Rani Therapeutics Holdings, Inc.

Rani Therapeutics is a clinical-stage biotherapeutics enterprise that develops oral delivery technologies for biologics and drugs, designed to replace traditional subcutaneous and intravenous injections. The company focuses on its proprietary, drug-agnostic RaniPill platform, which includes the RaniPill GO microtablet system and the RaniPill HC high-capacity liquid formulation capsule. Its therapeutic pipeline spans multiple indications, including obesity, inflammatory disorders, and rare diseases, featuring active candidates such as RT-114, RT-116, RT-111, and RT-117. Intended customers and commercial targets comprise partner biopharmaceutical firms seeking oral delivery mechanisms for proprietary compounds, alongside eventual end-users including patients, prescribing clinicians, and healthcare networks.

The business conducts preclinical evaluation and automated pilot manufacturing in-house while engaging external engineering contractors and global component suppliers. Clinical development activities and trial cohorts have operated across locations including Australia, with planned future commercialization spanning the United States, Europe, and Asia. Corporate headquarters and physical facility locations are not detailed in the provided excerpt, nor are formal founding dates or web domains specified.

Summary of the business section of Rani Therapeutics's latest annual report, written by StockData.

“As of December 31, 2025, we had 69 full-time employees and two part-time employees.”